Somaxon Pharmaceuticals Inc., of San Diego, said in an SEC filing that partner Procter & Gamble Co., of Cincinnati, elected not to exercise its option to negotiate for rights to an over-the-counter (OTC) version of insomnia drug Silenor (doxepin), under the terms of the companies' 2010 agreement

In other news, AMT reported that shareholders have approved all the resolutions proposed for a corporate restructuring and financing transaction, which will result in the assets and certain liabilities being acquired by a newly formed private company, uniQure BV...Astellas Pharma Inc., of Tokyo, and Vical Inc., of San Diego, finalized the design for a pivotal Phase III trial of TransVax cytomegalovirus vaccine for transplant recipients, triggering a $10 million milestone payment to Vical

It plans to file the draft registration submission in June for the repurposed medication designed to treat premature ejaculation...Illumina Inc., of San Diego, said its board has unanimously rejected Basel, Switzerland-based Roche AG's revised offer to acquire Illumina for $51 per share in cash and has urged stockholders not to tender shares. (See BioWorld Today, Jan. 26, 2012

Protox Therapeutics Inc., of San Diego, and Vancouver, British Columbia, changed its name to Sophiris Bio Inc...Vical Inc., of San Diego, and Astellas Pharma Inc., of Tokyo, finalized the design for a pivotal Phase III trial of TransVax cytomegalo vaccine for transplant recipients, triggering a $10 million milestone payment to Vical

Roche AG, of Basel, Switzerland, said it increased its offer to buy San Diego-based tools firm Illumina Inc...Illumina urged shareholders to defer taking action on the latest bid. (See BioWorld Today, Jan. 26, 2012

In other news, Addex reported top-line data showing that a Phase IIa trial testing dipraglurant, a small-molecule allosteric modulator, in Parkinson's disease patients suffering from debilitating levodopa-induced dyskinesia (LID) met its primary endpoint, with the drug exhibiting a good safety and tolerability profile...In other news, AstraZeneca said subanalysis data from its VOYAGER study suggested that achieving an LDL-C goal of less than 70 mg/dL or a greater than 50 percent reduction in LDL-C

Roche AG, of Basel, Switzerland, said it will extend its $5.7 billion offer to acquire tools firm Illumina Inc., of San Diego, to April 20...Valeant Pharmaceuticals International Inc., of Mississauga, Ontario, said it agreed to acquire Natur Produkt International JSC, a Russian specialty pharma firm that has a significant presence in over-the-counter brands

Amylin Pharmaceuticals Inc., of San Diego, and Eli Lilly and Co., of Indianapolis, gained the European Commission's approval to expand marketing of Byetta (exenatide twice-daily) as an adjunctive therapy to basal insulin, with or without metformin and/or Actos (pioglitazone, Takeda Pharmaceutical Co. Ltd.), for the treatment of Type II diabetes...Hyperion Therapeutics Inc., of San Francisco, acquired worldwide rights to Ravicti (glycerol phenylbutyrate) from Ucyclyd Pharma Inc., a subsidiary of

Tarsa and QS Pharma had a previous agreement for small-scale development batches which progressed to scale-up and validation activities that are currently under way...VistaGen Therapeutics Inc., of South San Francisco, entered a collaboration with Vala Sciences Inc., of San Diego, to advance drug safety screening methods in clinically relevant human in vitro bioassay systems

Under the terms, Flamel issued a $12 million senior note to Eclat Holdings LLC and agreed to pay Eclat Holdings an earnout payment of 20 percent of the gross profit generated by the Eclat launch products...In other news, Medivir said it will file an application in Europe to start Phase I trials of MIV-711, a cathepsin K inhibitor aimed at treating bone disorders such as osteoporosis, osteoarthritis or bone metastases

Illumina Inc., of San Diego, said its board sent a letter urging stockholders to reject the unsolicited bid by Basel, Switzerland-based Roche AG

Roche AG, of Basel Switzerland, said it received a request for additional information from the Federal Trade Commission in connection with its proposed acquisition of Illumina Inc., of San Diego, pursuant to the Hart-Scott-Rodino Antitrust Improvements Act of 1976...Roche said it would continue to work closely with the FTC to resolve any questions expeditiously. (See BioWorld Today, Jan. 26, 2012

In other news, Gentium said a Phase III trial evaluating defibrotide in preventing hepatic veno-occlusive disease (VOD) in pediatric patients undergoing hematopoietic stem cell transplantation (HSCT) showed that use of defibrotide led to a 40 percent reduction in the incidence of VOD 30 days after HSCT...Lanthio Pharma BV, of Groningen, the Netherlands, granted an exclusive license to Tarix Pharmaceuticals Inc., of Cambridge, Mass., for its lanthionine-stabilized angiotensin-(1-7) agonistic peptide

Roche AG, of Basel, Switzerland, said it extended its cash offer to acquire all outstanding shares of Illumina Inc., of San Diego, at a price of $44.50 per share, to 6 p.m

Lanthio Pharma BV, of Groningen, the Netherlands, granted an exclusive license to Tarix Pharmaceuticals Inc., of Cambridge, Mass., for its lanthionine-stabilized angiotensin-(1-7) agonistic peptide...OncoMed Pharmaceuticals Inc., of Redwood City, Calif., inked an agreement with Molecular Response LLC, of San Diego, to expand the companies' pilot program to develop patient-derived tumor xenografts through the use of Molecular Response's "living" cell bank of primary tumor cells

AVEO Pharmaceuticals Inc., of Cambridge, Mass., and Astellas Pharma Inc., of Tokyo, said they began a collaboration with the National Comprehensive Cancer Network (NCCN) Oncology Research Program to develop tivozanib for solid tumors...Receptos Inc., of San Diego, published a crystal structure for S1P1, a lipid G protein-coupled receptor (GPCR) in Science

commercial rights to gemcitabine, DARA's in-licensed cancer agent...Uman plans to file an abbreviated new drug application later this year...Santarus Inc., of San Diego, said the FDA accepted for filing its new drug application for Uceris (budesonide), a locally acting corticosteroid, for the induction of remission of mild to moderate active ulcerative colitis

Zealand Pharma A/S, of Copenhagen, Denmark, said partner Sanofi SA, of Paris, disclosed top-line data from the GetGoal-P Phase III study, showing lixisenatide, a once-daily glucagon-like peptide 1 agonist, hit its primary efficacy endpoint of significantly reducing blood glucose levels compared to placebo (p < 0.0001), with HbA1c decreasing from a mean baseline value of 8.08 percent to a mean value of 7.06 percent after 24 weeks in the lixisenatide group and from 8.05 percent to 7.59 percent in

Illumina Inc., of San Diego, said its board urged shareholders to reject the unsolicited $5.7 billion bid from Basel, Switzerland-based Roche AG...The big pharma has said it plans to nominate a slate of candidates for election to Illumina's board. (See BioWorld Today, Jan. 26, 2012